Compare BHRB & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHRB | SPRY |
|---|---|---|
| Founded | 1852 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 962.7M | 1.0B |
| IPO Year | N/A | N/A |
| Metric | BHRB | SPRY |
|---|---|---|
| Price | $68.37 | $8.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $71.67 | $35.00 |
| AVG Volume (30 Days) | 79.5K | ★ 1.3M |
| Earning Date | 01-22-2026 | 03-19-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | ★ 173.76 | N/A |
| EPS | ★ 7.72 | N/A |
| Revenue | ★ $340,508,000.00 | $142,772,000.00 |
| Revenue This Year | $37.10 | N/A |
| Revenue Next Year | $11.36 | $119.97 |
| P/E Ratio | $8.84 | ★ N/A |
| Revenue Growth | 46.12 | ★ 5459.66 |
| 52 Week Low | $47.57 | $6.66 |
| 52 Week High | $70.90 | $18.90 |
| Indicator | BHRB | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 34.60 |
| Support Level | $63.33 | $9.59 |
| Resistance Level | $70.90 | $10.11 |
| Average True Range (ATR) | 1.45 | 0.54 |
| MACD | 0.11 | -0.15 |
| Stochastic Oscillator | 46.90 | 8.81 |
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.